SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. is trending due to speculation around its defense and AI acquisitions, specifically Tiltan Software Engineering, and its potential impact on the company's market value to meet Nasdaq compliance. The community is focused on whether the company can maintain its listing and the potential for news related to contracts or partnerships in the defense sector. Some traders are setting price targets based on the low float and potential for a short squeeze, while others are wary of potential dilution and volatility.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending downwards, driven by concerns over increasing competition from Amazon and its recent deal with Netflix. Community discussions revolve around whether the stock is oversold, potential bottom levels, and CEO Jeff Green's strategy amidst these challenges, with some speculating about a possible acquisition or management change to revive investor confidence.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following an RBC Capital upgrade to Outperform, with a significantly raised price target driving bullish sentiment. Community discussions revolve around the potential for a short squeeze and the stock's long-term growth prospects in the African e-commerce market. Investors are also watching for a potential breakout above the $10 resistance level.

Slopana

Slopana is gaining traction as a Solana-based meme coin, with the community highlighting its strong meme potential and active presence on Phantom Wallet. Community members are drawn to its association with Solana, referencing the co-creator's term 'digital slop' and envisioning it as a potential mascot. The focus remains on community building and early entry, driving the current buzz.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is trending due to increasing interest in its fuel cell technology for powering AI data centers, with community members highlighting a recent price target increase from Morgan Stanley and discussing the company's potential for further growth. Investors are closely watching for new deals and partnerships, drawing comparisons to other energy companies and anticipating a potential short squeeze. The stock's momentum is fueled by growing demand for clean, reliable energy solutions in the rapidly expanding AI sector.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics is trending following news of a collaboration with Novartis for up to $5.7 billion, sending the stock soaring. The community is discussing the potential for further gains, analysts' price targets, and whether this deal makes the company a potential acquisition target. Some traders are skeptical, citing past performance and short-term profit-taking.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares

SOXS is trending as the community debates the sustainability of the current semiconductor rally, with some pointing to overbought conditions and potential for a significant pullback. Discussions include concerns about inflated valuations, the impact of potential tariffs, and comparisons to historical market bubbles. Traders are weighing whether recent market strength is a sign to short the sector or a continuation of the upward trend.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

PSNL is trending due to positive data from a lung cancer trial showcasing the effectiveness of their NeXT Personal MRD test, sparking optimism around potential reimbursement. Community discussions highlight the significance of the data, a new CIO hire, and a strategic collaboration with Tempus AI ($TEM). Some investors speculate on future revenue guidance and potential price targets contingent on reimbursement approvals.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's ($PLAY) is trending due to a significant after-hours drop following disappointing earnings, with revenue and profit missing expectations. The community is actively discussing potential downside risks and debating whether the new CEO can turn the tide amid economic headwinds. Some traders are also pointing to past incidents at the establishment.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the community discusses its correlation to Bitcoin's price movements and the impact of potential rate cuts. Some traders speculate on a possible short squeeze, while others express concerns about debt and dilution. Overall, community sentiment is mixed, with some anticipating a breakout and others remaining bearish.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth

ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.

Barclays has initiated coverage of Incyte (INCY) with an ‘Overweight’ rating and a $90 price target on Friday.The price target implies an over 20% upside to the stock’s closing price on Thursday.&nbsp;Shares of the company traded about 0.4% higher on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INCY">INCY</a> trended in the ‘bullish’ territory, accompanied by ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1332/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_2_26_04_PM_png_30d60d7ced.webp" alt="INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits" width="1332" height="126"><figcaption>INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits</figcaption></figure>The firm said that it sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.It believes the pivotal data for Tafasitamab in diffuse large B-cell lymphoma and the mid-stage data for Povorcitinib in chronic spontaneous urticaria patients provide the next legs of growth for Incyte.Earlier this week, Incyte said during its second-quarter earnings that it now expects late-stage data from the study evaluating Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma by the second half of 2025. Incyte is now focusing on its development pipeline as its cancer drug, Jakafi, nears patent expiration.“Continued progress and diversification of our portfolio, including advancements with povorcitinib and mutCALR, are strengthening the foundation for sustainable, long-term growth,” CEO Bill Meury said.Jakafi net revenue came in at $764 million in the second quarter of the year, marking a growth of 8% year-on-year, and accounting for about 63% of the company’s total revenue in the quarter of $1.216 billion, which surpassed Wall Street expectations. &nbsp;For the full year, the company is eyeing revenue of $3 billion to $3.5 billion from Jakafi.Another important drug from the company is its Opzelura cream, used to treat nonsegmental vitiligo, which brought in revenues of $164 million in the second quarter, marking a growth of 35% year-on-year.Overall, for the second quarter, the company reported an adjusted and diluted earnings per share of $1.57, compared to a loss per share of $1.82 reported in the corresponding period of 2024.According to data from Koyfin, 11 of 27 analysts covering the stock rate it ‘Buy’ or higher, while 15 rate it ‘Hold’, and just one rates it a ‘Sell’. The average price target on the stock is $79.87, representing an upside of about 6% from the current price.The stock is up by over 9% this year and by about 17% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pheton-holdings-dismisses-rumors-of-acquisition-by-gilead/chrEENyRdRR">Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer 

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.

Equity

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.


Why Incyte (INCY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of +12.95% and +5.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

INCY
Incyte Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INCY News

INCY Incyte Corp.